

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**VOLUNTARY ANNOUNCEMENT
ON-MARKET SHARE REPURCHASE
UNDER THE REPURCHASE MANDATE**

This announcement is made on a voluntary basis by Shandong Weigao Group Medical Polymer Company Limited* (the “**Company**”).

The board of directors of the Company (the “**Board**”) is pleased to announce that, in order to preserve the value of the Company, the Company intends to repurchase H shares of the Company (“**H Shares**”) in the open market from time to time pursuant to the general mandate to repurchase H shares granted to the Board by the shareholders of the Company at the annual general meeting of the Company held on 28 May 2024 and as amended by a special resolution passed on the extraordinary general meeting of the Company held on 16 October 2024. The Company will subsequently cancel, hold in treasury, sell or transfer the repurchased H Shares, if any, as deemed appropriate by the Board.

On 11 February 2025, the Company repurchased H Shares for the first time under such general mandate. A total of 50,000 H Shares has been repurchased on the open market at the aggregate repurchase amount of approximately HKD231,000 (excluding transaction fees), with the average repurchase price of HKD4.62 per H Share.

* For identification purpose only

Shareholders and potential investors should note that any repurchase to be made by the Company will be subject to market conditions and compliance with applicable laws and regulations, any regulatory requirements in connection with the repurchase as well as the provisions of the articles of association of the Company. The Company makes no assurance as to the timing, quantity or price of any repurchase of H Shares. Accordingly, shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

11 February 2025
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)
Mr. Cong Rinan (*Executive Director*)
Mr. Lu Junqiang (*Executive Director*)
Mr. Wang Daoming (*Executive Director*)
Mr. Tang Zhengpeng (*Non-executive Director*)
Mr. Chen Lin (*Non-executive Director*)
Ms. Yan Xia (*Non-executive Director*)
Mr. Li Guohui (*Independent Non-executive Director*)
Mrs. Meng Hong (*Independent Non-executive Director*)
Mr. Li Qiang (*Independent Non-executive Director*)
Mr. Sun Heng (*Independent Non-executive Director*)